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Background. We recently showed that two doses of 4 mg
of zoledronic acid (ZOL) ameliorated the bone loss and im-
proved bone histology within the first six months after kidney
transplantation. The aim of the present study was to evaluate
whether this early short-term intervention exhibited a sustained
bone-sparing effect.
Methods. A homogenous group of 20 de novo renal transplant
recipients were equally randomized to two infusions of 4 mg of
ZOL or placebo at two weeks and three months after engraft-
ment. Patients were followed up for three years by sequential
determination of bone densitometry and specific biochemical
markers.
Results. From month six to three years after transplanta-
tion, both treatment groups exhibited an improvement of bone
mineralization. Femoral neck bone mineral density z-scores in-
creased statistically significantly from −1.3 (2.6) to −0.2 (3.6)
in the placebo group and from −1.6 (2.9) to −1.2 (1.9) in the
ZOL group (median, range). Biochemical parameters of os-
teoblast activity such as osteocalcin and bone-specific alkaline
phosphatase did not increase significantly in both groups. Osteo-
protegerin, a marker of osteoclast inhibition, was significantly
elevated over the first six months in the ZOL group, but de-
creased to similar levels, as in the placebo group, over the next
two and a half years. Other markers of osteoclast activity such as
c-telopeptide of type 1 collagen, calcitonin, and intact parathy-
roid hormone were not different between six months and three
years in either group.
Conclusion. The early bone-sparing effect of short-term ZOL
therapy confers no sustained benefit versus placebo at three
year post-transplantation.
Post-transplant osteodystrophy remains a major
enigma after solid organ transplantation. The fracture
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rate in the first two years is reported to average 10%
in renal transplant recipients and is even higher in heart
and lung transplant recipients [1, 2]. The cumulative frac-
ture rate in patients transplanted more than five years
averages 44% [3]. The reasons for the high incidences
are many, but corticosteroid therapy has been shown to
be the main contributor [4]. The most severe loss of bone
mineralization density occurs within the first months af-
ter transplantation. Julian et al [5] reported a loss of bone
mineral density (BMD) in lumbar spine of almost 10%
within the first six to 18 months after transplantation [5].
This is the time frame when corticosteroid doses, used for
maintenance immunosuppression and to treat rejections,
are highest. Cumulative doses of roughly 5 to 10 g within
the first six months are standard in many centers. Only
recently, corticosteroid sparing or elimination regimens
are being evaluated in selected patients [6, 7]. Because
complete elimination of steroids is not recommendable
for most of the patients and calcineurin inhibitors have
also been shown to cause bone disease, post-transplant
osteodystrophy will also be a problem in the near future.
Besides bone specific side effects of immunosuppres-
sion, hyperparathyroidism is another main contributor
to osteodystrophy, especially in renal transplant patients
[8]. Hyperparathyroidism causes high turnover bone dis-
ease, which is functionally characterized by excessive ac-
tivation of osteoblasts and osteoclasts. The secondary
hyperparathyroidism usually subnormalizes within the
first weeks after successful renal transplantation, when
conversion of 24,25 to 1,25(OH)2 vitamin D3 functions
properly, as does enteral calcium resorption and renal
phosphate elimination.
In general, bone loss in the first months after trans-
plantation is well recognized, but conflicting data exist
on long-term bone turnover in patients after successful
renal transplantation. We recently showed that short-
term treatment of renal transplant recipients with two
injections of low dose zoledronic acid (ZOL), a third
generation bisphosphonate, at two weeks and three
months after engraftment could prevent the loss of bone
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Table 1. Cumulative or daily doses of drugs known to influence bone turnover/mineralization
Placebo N = 10 ZOL N = 9
0 to 6 months 7 months to 3 years P value 0 to 6 months 7 months to 3 years P value
Cumulative CSA dose g/6 months 45 (25) 32 (18) 0.012 43 (59) 30 (54) 0.018
Cumulative steroid dose g/6 months 2.9 (4.5) 1 (0.7) 0.005 2.9 (1.4) 0.7 (1.1) 0.008
Average dose of loop diuretics mg/day 0 (80) 0 (40) 0.28 0 (80) 0 (80) 1.0
Average dose of thiazide diuretics mg/day 0 (25) 0 (12.5) 0.66 0 (12.5) 0 (12.5) 1.0
Average dose of 1,25(OH)2 vitamin D3 lg/day 0 (0) 0 (0.25) 0.18 0 (0) 0.13 (0.5) 0.039
Average dose of calcium supplementation g/day 1(0) 0 (1) 0.003 1 (0) 0 (1) 0.007
Data are median and range. P values of changes between 0 to 6 and 7 months to 3 years in each group (Wilcoxon signed-rank test). No statistically significant
differences were observed between the placebo and the ZOL patients at three years.
mineralization and preserve the trabecular calcium con-
tent [9]. In that study, BMD at the femoral neck decreased
in the placebo group but was unchanged in the ZOL
group. The ZOL therapy led to an increase of BMD in
the lumbar spine but remained unchanged in the placebo
group. Serologic markers of bone turnover were signifi-
cantly lower in the ZOL-treated patients throughout the
six months of the trial. Renal transplant function was not
affected by bisphosphonate therapy.
The present study was performed to elucidate whether
these two doses of ZOL within the first three months af-
ter transplantation exerted long-term beneficial effects
on bone mineralization and turnover. For this purpose,
all subjects received BMD measurements and determina-
tion of serologic markers of bone turnover roughly three
years after transplantation.
METHODS
Study design and patients
Twenty patients from the University of Vienna Medical
School were randomized to receive either two doses of
4 mg zoledronic acid (ZOL, Novartis, Basel, Switzerland)
or placebo at week two and month three after successful
cadaveric renal transplantation. The study design, inclu-
sion and exclusion criteria, subjects’ demographic and
baseline characteristics, were described in detail previ-
ously [9]. In brief, patients receiving their first or second
cadaveric renal allograft were enrolled into the study
if they were normocalcemic and their renal transplant
function at two weeks was sufficient (i.e., serum creati-
nine <2 mg/dL) to allow bisphosphonate therapy. Pa-
tients were considered eligible for study participation
if baseline bone biopsy obtained during the transplant
surgery revealed no sign of adynamic bone disease de-
spite low intact parathyroid hormone (iPTH) levels. The
post-transplant immunosuppressive regimen consisted
uniformly of corticosteroids, mycophenolate mofetil, and
cyclosporine-Neoral (CSA). All patients received 1000
mg of daily calcium citrate in the first six months, but no
1,25(OH)2 vitamin D3 supplementation. Patients were
followed-up for almost three years after transplantation.
The median follow-up was 32 (11) months in the ZOL
and 33 (11) months in the placebo group. One dropout
occurred in the ZOL group because the patient refused
to attend the study follow-up visit at year three. There-
fore, a complete analysis of nine ZOL patients and all
10 subjects in the placebo group was possible three years
after renal transplantation.
The cumulative doses of immunosuppression and other
bone-relevant drugs within the first six months and be-
tween month six and three years are given in Table 1.
The results of the transiliacal crest biopsy at baseline
and at month six were reported previously [9].
Bone mineral density measurements
BMD was determined at baseline, at month six, and at
year three. Two different skeletal sites were measured at
each time point: lumbar spine at L1-L4 and the femoral
neck. Dual-energy x-ray absorptiometry (DEXA) and
a QDR-4500 scanner (Hologic, Waltham, MA, USA)
were used following the manufacturer’s recommenda-
tions. The results were expressed as z-scores.
Biochemical markers of bone metabolism
Biochemical markers of bone metabolism were deter-
mined at the same time points that densitometry was
performed. Markers for osteoclast differentiation or in-
hibition included osteoprotegerin, c-telopeptide of type
I collagen, calcitonin and intact parathyroid hormone
(iPTH). Biochemical indicators of osteoblast activity
were osteocalcin and bone-specific alkaline phosphatase.
Osteoprotegerin was determined by enzyme-linked
immunosorbentassay (ELISA), bone-specific alkaline
phosphatase by electrophoresis, 1,25(OH)2 vitamin D3
by radioimmunoassay, and all others by electrochemolu-
minescence techniques.
Statistical analysis
The sample size calculation was reported elsewhere
[9]. Because data were not normally distributed, values
are presented as median and range. Between-group dif-
ferences were evaluated by using the Mann-Whitney-U
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Fig. 1. Box-and-whisker plots of bone mineral densitometry measure-
ments of lumbar vertebrae and femoral neck at six months (open boxes)
and three years (gray boxes) after renal transplantation. The horizontal
lines in the boxes denote the 25th, 50th (median), and 75th percentile
values; the end of the whiskers denote the minimum and maximum val-
ues within 1.5 times the interquartile range from the 25th and 75th per-
centile values. No outliers are present. Patients were randomly treated
with either two doses of 4 mg zoledronic acid (ZOL, N = 9) or placebo
(N = 10) at week two and month three after transplantation. Both pa-
tient groups exhibited a statistically significant increase of femoral neck
z-scores but not in the lumbar spine. No between-group differences were
observed. ∗P < 0.05 month 6 vs. year 3 after transplantation. (Wilcoxon
signed-rank test: ZOL, P = 0.044; placebo, P = 0.021).
test, within-group differences by the Wilcoxon signed-
rank test.
P < 0.05 was considered statistically significant. The
SPSS software version 11.0.1 was used for analysis (SPSS,
Inc., Chicago, IL, USA). The study was approved by the
local Ethical Committee of the University of Vienna, and
subjects gave their informed written consent (EK 99/206;
to be found at http://ohrp.cit.nih.gov/search/asearch.asp).
RESULTS
Bone mineral density
BMD of the femoral neck increased statistically sig-
nificant in both groups from month six to year three
after transplantation. The increase in BMD z-scores of
the lumbar spine in the same time interval, however, did
not reach statistical significance in the ZOL group and
was unchanged in the placebo group (Fig. 1). The me-
dian z-scores were around –1 in the lumbar spine and
around –1.5 in the femoral neck region at month six af-
ter transplantation, suggesting no severe demineraliza-
tion of bone. Despite the relatively high baseline values
for renal transplant patients, mineralization of cancellous
bone increased in both treatment arms. No statistically
significant differences could be detected between the
treatment groups at any time after transplantation.
Two incidental vertebral compression fractures oc-
curred in each treatment group between month six and
year three after engraftment.
Biochemical markers of bone turnover
Biochemical markers of bone disease and serum crea-
tinine split by treatment group are given in Table 2. Re-
nal allograft function was good in both treatment groups
at month six and did not markedly deteriorate over the
follow-up period. It is of note that subjects with a serum
creatinine above 2 mg/dL two weeks after transplanta-
tion were considered ineligible for bisphosphonate ther-
apy and thus were not enrolled into the study.
Markers of osteoclast activity. Osteoprotegerin, which
inhibits osteoclast differentiation/maturation and activ-
ity was statistically higher at month six after transplan-
tation in the ZOL group compared with the placebo
group (P = 0.035). The inhibitory effect of the bispho-
sphonate on osteoclastic activity ceased thereafter and
osteoprotegerin returned to similar levels as observed in
the placebo group. Accordingly, c-telopeptide, which is
a marker of osteoclast activity, was suppressed at month
six in the ZOL group compared with the placebo group
(P = 0.028). C-telopeptide levels increased thereafter to-
ward values that were observed in the placebo group.
Calcitonin, an inhibitor of osteoclast activity, and iPTH,
an osteoclast activator, nearly normalized within the first
months after transplantation, not being different within
and between groups from month six to year three. Espe-
cially the secondary hyperparathyroidism at transplanta-
tion almost completely reversed within the first months
of proper renal allograft function. Accordingly, adequate
conversion of 24,25(OH)2 D3 to bioactive 1,25(OH)2
vitamin D3 occurred within the first six months in both
Schwarz and Mitterbauer et al: Zoledronic acid after renal transplantation 307
Table 2. Biochemical bone markers and serum creatinine
Placebo N = 10 ZOL N = 9
6 months 3 years P value 6 months 3 years P value
Osteoclast differentiation-inhibition
Osteoprotegerin pmol/L 6 (8) 5 (11) 0.91 10 (21) 5 (4) 0.12
C-telopeptide nmol/L 7 (12) 6 (11) 0.52 3 (8) 4 (4) 0.40
Calcitonin pg/mL 6 (15) 6 (20) 1.00 10 (17) 6 (18) 0.67
iPTH pg/mL 80 (162) 96 (369) 0.20 79 (347) 80 (163) 0.52
Vitamin D3 pg/mL 22 (79) 28 (67) 0.12 33 (39) 36 (37) 0.50
Osteoblast activity
Osteocalcin ng/mL 43 (80) 57 (218) 0.39 13 (91) 38 (45) 0.19
Bone specific alkaline phosphatase U/L 22 (36) 22 (54) 0.75 15 (42) 23 (21) 0.12
Serum calcium mmol/L 2.5 (0.4) 2.4 (0.5) 0.19 2.4 (0.7) 2.4 (0.7) 0.78
Serum phosphate mmol/L 0.9 (0.8) 1.1 (0.5) 0.06 0.8 (1.1) 1.0 (0.4) 0.16
Serum creatinine mg/dL 1.5 (0.8) 1.7 (2.1) 0.20 1.3 (1.2) 1.4 (1.9) 0.31
Data are median and range. P values of changes between 6 months and 3 years in each group (Wilcoxon signed-rank test). No statistically significant differences were
found between the placebo and ZOL group at three years.
groups and continued to be sufficient within the next
years.
Osteoblast metabolism. Osteocalcin, which is a non-
collagenous protein that is synthesized by osteoblasts
and correlates with bone formation, was suppressed in
the ZOL group at month six compared with the placebo
group. During the follow-up period, the effects of early
ZOL therapy on osteoblast activity obviously ceased and
osteocalcin returned to values not different to placebo-
treated patients. These data are inversely correlated with
the inhibitory effects of ZOL on osteoclasts. The other
investigated marker of osteoblast activity, bone-specific
alkaline phosphatase, showed identical regulation to os-
teocalcin. Bone-specific alkaline phosphatase was lower
in the ZOL patients at month six and increased thereafter
to values not different to the placebo group. Serum cal-
cium and phosphate were similar in both groups at every
time point (Table 2).
Acute rejections and bone-affecting medication
In the first six months three biopsy-proven acute rejec-
tions, all Banff 2a, occurred in the placebo group, and two
in the ZOL group. All rejections were successfully treated
with 3 mg/kg/d anti–T-lymphocyte globulin for 10 to
14 days (either ATG-Fresenius, Bad Homburg, Germany
or Thymoglobuline-Pasteur Me´rieux, Lyon, France). No
acute rejections occurred after the first six months, with
the exception of one clinically suspected but not biopsy-
confirmed rejection in the ZOL group, which was success-
fully treated with three days of 100 mg dexamethasone.
The cumulative corticosteroid dose was not different be-
tween the groups, but was statistically significantly higher
in the first months after transplantation compared with
the time thereafter. The median (range) daily steroid dose
at three years was 4 (3) mg in the ZOL and 3 (5) mg in
the placebo group respectively (P = 0.133). Three pa-
tients in each group received lipid-lowering therapy with
either 10 or 20 mg of atorvastatin at three years (P = 1.0).
No between-group differences could be observed in the
average dose of loop diuretics or thiazides at any time
point. Diuretic use was not different in the first half year
than thereafter. The cumulative dose of CSA was equal
in both groups, and doses were higher in the first months
than thereafter (Table 1).
DISCUSSION
In the present paper we report the three-year follow-
up of patients who were randomized to short-term ZOL
or placebo treatment. Two doses of 4 mg of ZOL at
two weeks and three months prevented bone loss within
the first six months after transplantation as evidenced by
an increase in trabecular calcium content. Placebo-, but
not ZOL-treated patients, lost bone mineral density at
femoral neck in the first six months. The BMD of the lum-
bar spine increased in the ZOL group but remained un-
changed in the placebo group in that period. From month
six onwards, femoral neck BMD increased in both groups,
being statistically higher at three years than at six months.
This effect is most likely driven by the resolution of the
secondary hyperparathyroidism within the first months
after transplantation and by the fact that corticosteroid
doses are significantly higher early after transplantation
than doses used for maintenance immunosuppression af-
ter the first half year. The BMD of lumbar spine at three
years was not statistically different to the six-month re-
sults in either group; ZOL-treated patients, however, ex-
hibited a trend toward increased BMD compared with
six-month readings. The lack of statistical significance
might reflect a type two error caused by the low num-
ber of patients in our study. This trend toward increased
BMD of cancellous bone after ZOL therapy is supported
by previous papers using other third-generation bispho-
sphonates after renal transplantation [10, 11].
As shown in the analysis of biochemical bone markers,
iPTH levels regressed to subnormal values within the first
months after engraftment and stayed in that range over
the next years in the investigated population with good
renal allograft function. Osteoprotegerin, also known as
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RANK [receptor activator of nuclear factor (NF)-jB],
inhibits osteoclast maturation and activity. We recently
were able to show in patients undergoing renal transplan-
tation that a combination of low osteoprotegerin and el-
evated iPTH best predicted morphologic chances of high
turnover bone disease and decreased bone mineraliza-
tion [12]. Osteoprotegerin was significantly elevated and
iPTH suppressed at month six in the ZOL group, suggest-
ing adequate osteoclast inhibition by the bisphosphonate.
At year three after transplantation, values had returned
to their normal/subnormal range in the ZOL group, indi-
cating a nonsustained ZOL effect on osteoclasts.
Osteoblast activity was monitored by sequential de-
terminations of osteocalcin and bone-specific alkaline
phosphatase serum levels. Both markers showed a trend,
although not statistically significant, toward an increase
over time in both groups, suggesting active osteoblastic
apposition of mineralized bone, which is reflected by in-
creased femoral BMD at three years.
A recent paper by Fan et al [11] used a similar study
protocol to ours. Like their results, we found that patients
who received two doses of a third-generation bisphos-
phonate did not experience significant bone loss in the
femoral neck in the early phase after renal transplanta-
tion. We could even demonstrate a significant increase
in lumbar spine BMD in ZOL-treated patients. In the
follow-up study at four years, Fan et al reported a signif-
icant loss of femoral neck BMD of 12% in the placebo
group. The decrease in lumbar spine BMD averaged 5%
but did not reach statistical significance. Pamidronate-
treated patients did not experience a statistically signif-
icant bone loss, neither at the femoral neck nor at the
lumbar spine over the four-year study period. We did
not find a long-term effect of short-term bisphosphonate
therapy because both groups increased with their femoral
neck BMD and exhibited unchanged lumbar spine BMD.
A likely explanation is the fact that early bone loss was
only moderate in our patients, even in the placebo group.
ZOL-treated patients experienced an average loss of only
2.9% of BMD given in g/cm2 in the femoral neck and
improved by roughly 3% in lumbar spine BMD in the
first six months [9]. Therefore, no big improvement could
be expected long-term after transplantation. The reason
for the overall well-preserved mineralization density in
our patients is the specific prophylaxis and treatment of
emerging and existing pretransplant bone disease, mainly
by controlling hyperparathyroidism. Another explana-
tion for the different findings in the studies is the differ-
ence in bisphosphonate type and dose. Fan used 0.5 mg/kg
pamidronate at transplantation, and at month one we in-
fused 4 mg ZOL twice within three months after engraft-
ment. Direct comparisons of single doses of pamidronate
(90 mg) with ZOL (2 and 4 mg) in non-transplant pa-
tients with osteolysis showed equal efficacy on hard end
points, such as skeletal disease progression to the point
where radiation therapy was required [13, 14]. Last but
not least, the difference between the two studies might be
explained by the loss of 35% of patients during follow-up
in the Fan study, whereas only one patient did not com-
plete the three-year follow-up visit in our study.
As indicated by the biochemical resolution of osteo-
clast inhibition after the first six months in the ZOL
group, it may be worth studying if longer-term bispho-
sphonate therapy exhibits additional beneficial effects
to steroid minimization and spontaneous resolution of
hyperparathyroidism on BMD long-term after transplan-
tation. Because of the relative lack of published evi-
dence, no clear recommendation currently exists on the
use of bisphosphonates long-term after renal transplan-
tation. There is good agreement among researchers that
short-term use of new generation bisphosphonates in pa-
tients after kidney transplantation with high turnover re-
nal osteodystrophy is beneficial, although studies using
hard end points such as fracture rates are missing. The
short-term use of bisphosphonates in renal transplant pa-
tients with low turnover bone disease is less clear and
sometimes even considered a relative contra-indication
because of the potential risk of adynamic bone dis-
ease. On the other hand, bisphosphonates predominantly
inhibit osteoclasts and to a lesser extent osteoblasts.
Recent evidence even suggests that bisphosphonates pro-
long osteoblast survival in glucocorticoid-induced de-
pression of bone formation [15]. Thus, bisphosphonate
therapy should lead to a positive bone balance, despite
the presence of low bone turnover before transplanta-
tion. Indeed, as shown in our previous trial, none of the
three subjects with low turnover bone disease at base-
line that received low dose bisphosphonate therapy ex-
hibited signs of adynamic bone disease or osteomalacia
in the follow-up bone biopsy at six months [9]. Further-
more, low turnover osteodystrophy is often used syn-
onymously with hypoparathyroidism in the absence of
morphologic results in renal transplant patients, but re-
cent papers failed to demonstrate a close correlation be-
tween serum iPTH levels and histologic readings [12, 16].
Grotz et al [10] recently demonstrated that one year
post renal-transplant bone loss can be prevented by iban-
dronate at months three, six, and nine. Long-term follow-
up data on these patients are not available yet, however.
According to an earlier paper by Grotz et al [17], in which
the authors found that bone loss two years after renal
transplantation was not different in the renal transplant
population compared with the matched general popula-
tion, we also found no loss in the lumbar spine BMD at
three years after transplantation in either group.
CONCLUSION
We have shown that BMD of cancellous bone im-
proved in ZOL- and placebo-treated renal transplant
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patients from month six onward. Resolution of hyper-
parathyroidism and low maintenance steroid doses are
likely to be responsible for this effect. Short-term bene-
fits of ZOL therapy did not result in sustained effects on
bone BMD in our renal transplant population with only
mild osteopathy.
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